A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Summary

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

Timeline

Start

2024-02-12

Primary completion

2027-10

Completion

2028-04

Drugs

Indications